Gentrack Group (ASX:GTK, NZE:GTK) received notice that Regal Funds Management, a unit of Regal Partners (ASX:RPL), decreased its holdings in the company to 8.748% from 9.79%, according to a Friday filing with the New Zealand bourse.
Regal Funds now owns 9.8 million shares in the company, the filing said.
Meridian Energy (NZE:MEL, ASX:MEZ) "welcomed" a fast-track panel draft decision to relax operating limits at Lake Pukaki, allowing use of water stored between 518 and 513 meters above sea level for three years, ahead of a Transpower-estimated 4% electricity shortage risk threshold, according to a Friday filing with the Australian and New Zealand bourses.The company acknowledged stakeholder concerns regarding eased access to contingent storage and proposes that, if the draft is confirmed, half of the five meters of contingent storage continue to be restricted to periods of heightened supply security risk for the remainder of the year, given the positive hydro outlook for winter, the filing said.The draft decision also approves permanent rock armoring at Pukaki Dam to improve resilience against wave erosion under lower lake operating levels.The panel's final decision is due by July 3, the filing added.
LongBio Pharma (HKG:1779) raised HK$1.25 billion in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$96.06 per H-share, according to a Thursday after-market filing with the Hong Kong Stock Exchange.The Chinese biopharmaceutical company offered 14.2 million H-shares in the global offering.The Hong Kong public offer was 4,762.58 times subscribed, with a final allocation of 1.4 million shares, representing 10% of the total offering.The international offering was 10.94 times subscribed, with a final allocation of 12.8 million shares, or 90% of the total offering.An over-allocation of 2.1 million shares was made under the global offering.Cornerstone investors, including OrbiMed Genesis, The Biotech Growth Trust, TruMed Innovation Fund, TruMed Master Fund, Shanghai Gaoyi, Wisdomshire Asset Management, Vision Fund 1, and GSC Fund 1, were allotted a combined 7.1 million shares, representing 49.96% of the global offering, according to the filing.LongBio Pharma is set to debut on the Hong Kong bourse on Friday, June 5.
Dajin Heavy Industry (HKG:1081, SHE:002487) raised HK$6.47 billion in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$66.40 per H-share, the maximum offer price of the deal, according to a Thursday after-market filing with the Hong Kong Stock Exchange.The China-based offshore wind power equipment provider offered 100 million H-shares in the global offering after fully exercising the offer size adjustment option.The Hong Kong public offer was 134.39 times subscribed, with a final allocation of 8.7 million shares, representing 8.7% of the total offering.The international offering was 10.68 times subscribed before the exercise of the offer size adjustment option, with a final allocation of 91.3 million shares, or 91.3% of the total offering.An over-allocation of 15 million shares was made under the global offering.Cornerstone investors, including GIC, HHLRA, HIM, CPE Juniper, UBS AM Singapore, Taikang Life, Eastspring Singapore, and Eastspring HK, were allotted a combined 42.2 million shares, representing 42.21% of the global offering, according to the filing.Dajin Heavy Industry is scheduled to debut on the Hong Kong bourse on Friday, June 5.